While stressing that the ON TRIPS agreement gives governments flexibility to take steps to promote access to medicines, the declaration also recognizes the importance of intellectual property protection for the development of new medicines. It also reaffirms the commitments made by WTO members under the TRIPS agreement. For WTO members in the least developed countries, the declaration states that they will not have to protect undisclosed patents and information rights on medicines until 2016. For these rights, the least developed countries therefore have ten more years to apply the TRIPS rules. In 2008, it was decided to extend the deadline for the adoption of the amendment to the TRIPS agreement. The deadline has been extended until December 31, 2009 or “as late as the ministerial conference can be decided.” [3] The General Council extended the 2011 deadline to 31 December 2013. [4] The panel on the WTO dispute over Australia and the simple packaging of tobacco products concluded that the Doha Declaration on the TRIPS and Public Health Agreement of 2001 was an agreement that changed the interpretation of the TRIPS agreement. The Doha Declaration was well received and considered by many public health officials to be an important step in prioritizing public health over intellectual property rights “in certain situations.” [5] However, there are other problems and barriers to access to medicines, such as lack of resources and infrastructure.B. [5] Pascal Lamy, EU Trade Commissioner at the time of the declaration, said the agreement had “solved about 10% of the problem of developing countries` access to medicines”. [5] The adoption of the Trade-Related Intellectual Property Rights Agreement (TRIPS) under the World Trade Organization (WTO) has significantly changed the international intellectual property landscape, particularly with regard to access to medicines. One of the stated objectives of the TRIPS agreement was to contribute to technological innovation, the transfer and dissemination of technologies, to the mutual benefit of technology manufacturers and users, in a way that promotes social and economic well-being, and to a balance of rights and obligations.